08:17 EDT Aldeyra (ALDX) receives Complete Response Letter from FDA for Reproxalap NDA
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Aldeyra options imply 29.5% move in share price post-earnings
- Aldeyra options imply 30.8% move in share price post-earnings
- Aldeyra Therapeutics: Buy Rating Affirmed on Promising Reproxalap and Strategic RASP Market Expansion
- Biotech Alert: Searches spiking for these stocks today
- Aldeyra Therapeutics: Strategic Pipeline Advancements and Financial Stability Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue